Headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.3769402982717 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of equities research analysts have weighed in on AERI shares. Needham & Company LLC restated a “buy” rating and issued a $65.00 target price on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. Mizuho restated a “buy” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Wednesday, September 20th. Canaccord Genuity restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, September 22nd. Cowen restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. Finally, Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $72.00.
Aerie Pharmaceuticals (AERI) traded up $0.75 on Thursday, hitting $58.80. The stock had a trading volume of 191,505 shares, compared to its average volume of 277,563. The stock has a market capitalization of $2,160.00, a price-to-earnings ratio of -17.55 and a beta of 1.11. Aerie Pharmaceuticals has a one year low of $37.95 and a one year high of $66.60. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/11/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-aerie-pharmaceuticals-aeri-stock-price.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.